The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial
Abstract
BACKGROUND In the treatment of de-novo coronary small vessel disease, drug-coated balloons (DCBs) are non-inferior to drug-eluting stents (DESs) regarding clinical outcome up to 12 months, but data beyond 1 year is sparse. We aimed to test the long-term efficacy and safety of DCBs regarding clinical endpoints in an all-comer population undergoing percutaneous coronary intervention. METHODS In this prespecified long-term follow-up of a multicentre, randomised, open-label, non-inferiority trial, patients from 14 clinical sites in Germany, Switzerland, and Austria with de-novo lesions in coronary vessels <3 mm and an indication for percutaneous coronary intervention were randomly assigned 1:1 to DCB or second-generation DES and followed over 3 years for major adverse cardiac events (ie, cardiac death, non-fatal myocardial infarction, and target-vessel revascularisation [TVR]), all-cause death, probable or definite stent thrombosis, and major bleeding (Bleeding Academic Research Consortium bleeding type 3-5). Analyses were performed on the full analysis set according to the modified intention-to-treat principle. Dual antiplatelet therapy was recommended for 1 month after DCB and 6 months after DES with stable symptoms, but 12 months with acute coronary syndromes. The study is registered with ClinicalTrials.gov, NCT01574534 and is ongoing. FINDINGS Between April 10, 2012, and Feb 1, 2017, of 883 patients assessed, 758 (86%) patients were randomly assigned to the DCB group (n=382) or the DES group (n=376). The Kaplan-Meier estimate of the rate of major adverse cardiac events was 15% in both the DCB and DES groups (hazard ratio [HR] 0·99, 95% CI 0·68-1·45; p=0·95). The two groups were also very similar concerning the single components of adverse cardiac events: cardiac death (Kaplan-Meier estimate 5% vs 4%, HR 1·29, 95% CI 0·63-2·66; p=0·49), non-fatal myocardial infarction (both Kaplan-Meier estimate 6%, HR 0·82, 95% CI 0·45-1·51; p=0·52), and TVR (both Kaplan-Meier estimate 9%, HR 0·95, 95% CI 0·58-1·56; p=0·83). Rates of all-cause death were very similar in DCB versus DES patients (both Kaplan-Meier estimate 8%, HR 1·05, 95% CI 0·62-1·77; p=0·87). Rates of probable or definite stent thrombosis (Kaplan-Meier estimate 1% vs 2%; HR 0·33, 95% CI 0·07-1·64; p=0·18) and major bleeding (Kaplan-Meier estimate 2% vs 4%, HR 0·43, 95% CI 0·17-1·13; p=0·088) were numerically lower in DCB versus DES, however without reaching significance. INTERPRETATION There is maintained efficacy and safety of DCB versus DES in the treatment of de-novo coronary small vessel disease up to 3 years. FUNDING Swiss National Science Foundation, Basel Cardiovascular Research Foundation, and B Braun Medical.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Self-citationClinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Third Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., Thygesen, K., Alpert, J. S., White, H. D., Jaffe, A. S., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.001 · Cited by 2,621
2018 ESC/EACTS Guidelines on myocardial revascularization
Neumann, F. J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2018) · Kardiologia Polska · doi:10.5603/kp.2018.0228 · Cited by 1,126
Katsanos, K., Spiliopoulos, S., Kitrou, P., Krokidis, M., & Karnabatidis, D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.011245 · Cited by 1,020
Drug-Coated Balloons for Coronary Artery Disease
Jeger, R. V., Eccleshall, S., Wan Ahmad, W. A., Ge, J., Poerner, T. C., Shin, E.-S., Alfonso, F., Latib, A., Ong, P. J., Rissanen, T. T., et al. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.02.043 · Cited by 600
Self-citationLatib, A., Colombo, A., Castriota, F., Micari, A., Cremonesi, A., De Felice, F., Marchese, A., Tespili, M., Presbitero, P., Sgueglia, G. A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.020 · Cited by 364
Cortese, B., Micheli, A., Picchi, A., Coppolaro, A., Bandinelli, L., Severi, S., & Limbruno, U. (2010) · Heart · doi:10.1136/hrt.2010.195057 · Cited by 338
Metadata
- Authors
- Jeger, R. V., Farah, A., Ohlow, M.-A., Mangner, N., Möbius-Winkler, S., Weilenmann, D., Wöhrle, J., Stachel, G., Markovic, S., Leibundgut, G., Rickenbacher, P., Osswald, S., Cattaneo, M., Gilgen, N., Kaiser, C., Scheller, B., Ammann, P., Awad, B., Baumgartner, M., Boehm, M., Bohl, S., Bruch, L., Buckert, D., Buser, P., Butter, C., Clever, Y. P., Cremers, B., Cuculi, F., Dannberg, G., Erne, P., Ewen, S., Fahrni, G., Franz, M., Haager, P., Harder-Allgoewer, A., Hoffmann, A., Höllriegel, R., Hölschermann, F., Jerichow, T., Joerg, L., Kapos, I., Keweloh, B., Kherad, B., Kühne, M., Lauer, B., Lenk, K., Lenz, C., Von Lewinski, D., Linke, A., Luha, O., Maeder, M., Mahfoud, F., Mueller, C., Neuss, M., Niederl, E., Noutsias, M., Nuessli, D., Oenal, I., Otto, S., Paliskyte, R., Perl, S., Pieske, B., Plicht, B., Poerner, T. C., Richter, S., Rickli, H., Riede, F., Roelli, H., Roettgen, A., Rohner, F., Schirmer, S., Schmidt, A., Schreiber, M., Seidel, M., Stephan, F.-P., Sticherling, C., Struck, B., Surber, R., Tambor, G., Toggweiler, S., Trachsel, L., Twerenbold, R., Wagner, A., Wein, B., Winkler, S., Winzer, E., Wolf, A., Zellweger, M., Krackhardt, F., & Zweiker, R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 396
- Issue
- 10261
- Pages
- 1504-1510
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3094011070
- Cited by
- 279
- References
- 17
- FWCI
- 19.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32173-5
- The paper
- Jeger, R. V., Farah, A., Ohlow, M.-A., Mangner, N., Möbius-Winkler, S., Weilenmann, D., Wöhrle, J., Stachel, G., Markovic, S., Leibundgut, G., Rickenbacher, P., Osswald, S., Cattaneo, M., Gilgen, N., Kaiser, C., Scheller, B., Ammann, P., Awad, B., Baumgartner, M., . . . Zweiker, R. (2020). Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)32173-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.